Follow the CRESCENT BIOPHARMA, INC. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.5bn. The latest transaction was disclosed on 20 July 2026 (Acquisition). Among the most active insiders: Fairmount Funds Management LLC. All data is free.
17
Insider Decl.
n/a
Thresholds
€26m
2 ops.
Buy Volume
n/a
7 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate CRESCENT BIOPHARMA, INC. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
40Σ signal
Buys €26mn/a Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.